Form 4: Aura Biosciences CTO Boosts Equity Holdings

Aura Biosciences' Chief Technology Officer, Mark Plavsic, acquired 62,339 shares via restricted stock units and 112,661 stock options.

Summary

• Mark Plavsic, Chief Technology Officer of Aura Biosciences, acquired 62,339 shares of common stock through a Restricted Stock Unit (RSU) award on March 2, 2026.
• These RSUs were acquired at a price of $0 per share and are scheduled to vest in four substantially equal annual installments beginning January 15, 2027, contingent on continued service.
• Plavsic also acquired 112,661 stock options on March 2, 2026, with an exercise price of $6.14 per share and an expiration date of March 2, 2036.
• The stock options vest 25% on February 1, 2027, with the remaining portion vesting pro-rata in 36 monthly installments thereafter, subject to continued service.
• Following these transactions, Plavsic beneficially owns 243,736 shares of common stock and 112,661 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a key executive's increased stake and long-term commitment to the company through equity awards, aligning their interests with shareholders.

Positives

• Aura Biosciences' Chief Technology Officer, Mark Plavsic, increased his beneficial ownership in the company through new equity awards, aligning his interests with shareholders.
• The awards are structured with multi-year vesting schedules, indicating a long-term commitment from a key executive to the company's future performance.

Future Outlook

The equity awards granted to the Chief Technology Officer are structured with multi-year vesting schedules, indicating a long-term incentive for executive retention and performance aligned with future company growth.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units and stock options with multi-year vesting, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This aligns executive interests with long-term shareholder value creation, a common strategy among peers like Moderna or BioNTech.

Comparison to Industry Standards

• The use of RSUs and stock options for executive compensation is a common practice across the biotech industry, comparable to compensation structures seen at companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, which also utilize long-term equity incentives to align management with shareholder interests.
• The vesting schedules, extending several years into the future (e.g., RSUs vesting until 2027 and options vesting over 36 months after an initial cliff), are typical for executive retention programs in high-growth sectors, similar to those observed at emerging biotechs like Alnylam Pharmaceuticals or CRISPR Therapeutics.

Stakeholder Impact

• Shareholders: Increased alignment of a key executive's interests with long-term shareholder value. Potential for minor dilution from future share issuance upon RSU vesting and option exercise.
• Employees: May signal confidence in the company's future, potentially boosting morale.

Next Steps

• Continued service of Mark Plavsic for the vesting of RSUs and stock options.
• Vesting of RSUs in four substantially equal annual installments beginning January 15, 2027.
• Vesting of stock options: 25% on February 1, 2027, with the remainder pro-rata in 36 monthly installments.

Key Dates

Recommendation

The filing indicates a key executive, the Chief Technology Officer, has received significant equity awards (RSUs and stock options) with long-term vesting schedules. While this demonstrates management's continued commitment and aligns their interests with shareholders, it is a compensation event rather than an open market purchase. Therefore, it primarily reinforces a 'hold' position, suggesting stability and executive confidence, but does not present new fundamental information warranting a 'buy' or 'sell' solely based on this Form 4.

Keywords

Aura Biosciences, AURA, Mark Plavsic, Chief Technology Officer, CTO, Insider Transaction, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Beneficial Ownership